ClinicalTrials.gg
RecruitingNCT06360393OUTERSPACE-3Updated Nov 16, 2026

Inhaler Adherence and Inhalation Technique Assessed by a Smart Spacer in Patients With Severe Asthma on Biologics

An observational study in Asthma, sponsored by University Medical Center Groningen. Recruiting at 5 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University Medical Center Groningen · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Asthma by University Medical Center Groningen — 2 open to participants now, 2 under way, none of them phase 3. Asthma · University Medical Center Groningen.

Started
2024
the only one that year
Observational
7 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Asthma by University Medical Center Groningen, this one is the only one that started in 2024, is one of 7 observational ones, and was the 10th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 11 studies in Asthma by University Medical Center Groningen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Asthma by University Medical Center Groningen, or all of them as a file.
02

Study summary

Severe refractory asthma affects about 3.5% of asthma patients, often necessitating biologic therapy in addition to standard treatment. However, little is understood about maintenance and reliever inhalation medication adherence in these cases which might impact overall biologic response. Objectively monitoring inhalation medication adherence remains a significant challenge. The Smart AeroChamber® device, capable of measuring adherence and inhalation technique, is untested in severe asthma patients on biologics, presenting a potentially cost-effective solution to monitor adherence and better understand treatment response.

This study aims to assess the feasibility of the Smart AeroChamber® device in severe asthma patients on biologic therapy, with objectives to:

  1. Evaluate inhalation medication adherence patterns and inhaler technique, and comparing that adherence data with traditional measures e.g. the Test of Adherence to Inhalers (TAI), and an inhalation technique checklist.
  2. Investigate the association between inhaled medication adherence and clinical outcomes such as exacerbations, short-acting beta-agonists (SABA) use, oral corticosteroids use (OCS), Fractional Exhaled Nitric Oxide (FeNO), blood eosinophil count, and Asthma Control Questionnaire (ACQ) scores.
  3. Assess patient and healthcare provider satisfaction and usability of the Smart AeroChamber® device.

The study design is prospective and observational, with a sample size of 110 adult patients diagnosed with severe asthma using biologic therapy. Participants will be followed for 12 months, during which they will receive Smart AeroChamber® devices. These devices will measure medication adherence and inhaler technique, and undergo assessments of clinical outcomes at regular intervals. Usability and satisfaction will also be evaluated using the Systems Usability Scale (SUS) in patients and healthcare professionals.

The study will be conducted across five severe asthma clinics in the Netherlands. Data analysis will involve comparing the inhalation medication adherence data with traditional measures for adherence and inhalation technique, assessing clinical outcomes, and evaluating usability and satisfaction. The findings from this study will provide insights into the feasibility and effectiveness of using digital devices like the Smart AeroChamber® to support medication adherence and possibly improve outcomes in patients with severe asthma on biologic therapy.

Read the detailed description

Rationale:

Despite the availability of effective inhaled medications, 15% of asthma patients remain uncontrolled on medium to high dose inhaled corticosteroids (ICS) and LABA, comprising difficult-to-treat asthma and severe refractory asthma groups. GINA guidelines stress the importance of assessing adherence and technique before step-up treatment due to associated risks and costs.

Research underscores the efficacy and cost-effectiveness of investing in adherence and technique support, particularly in this population. However, there is limited understanding of ICS adherence during biologic therapy, despite its increasing use. Studies on biologics like mepolizumab suggest associations between ICS adherence and improved outcomes, while data on others like benralizumab are less conclusive.

Indeed, non-adherence and poor technique is widely reported in patients with all severities of asthma and is associated with increased morbidity and economic burden. Objectively assessing and enhancing adherence remains one of the major challenges for physicians, pharmacists and nurses. Limited studies on digital tools for adherence management exist, particularly for pMDIs in combination with spacers. Digital technologies are promising in addressing these challenges, but studies on devices capable of objectively measuring adherence and technique, especially in patients using pMDIs, are lacking. The Smart AeroChamber® device presents an innovative solution, showing potential in clinical trials for asthma and COPD. The Smart AeroChamber® is a CE-certified device. However, its application in severe asthma patients on biologics remains unexplored, presenting an opportunity to enhance adherence support and treatment outcomes in this cost-sensitive population.

The aim:

This study aims to evaluate the feasibility of using a Smart Spacer device in patients with severe asthma who are on biologic therapy. The research aims to achieve several objectives:

  1. Assess medication adherence patterns and inhaler technique using the Smart Spacer device and compare the data with traditional adherence measures, such as the Test of Adherence to Inhalers (TAI), and an inhalation technique checklist.
  2. Evaluate the association between adherence measured by the Smart Spacer device and various clinical outcomes including exacerbations, use of short-acting beta agonists (SABA) and oral corticosteroids (OCS), Fractional exhaled Nitric Oxide (FeNO) results, blood eosinophil count, and asthma control questionnaire (ACQ) scores.
  3. Assess the usability and satisfaction of patients and healthcare providers with the Smart Spacer device, using the System Usability Scale (SUS).

Study Design:

This study adopts a prospective, observational design.

Inclusion Criteria:

Participants eligible for inclusion are adults aged over 18 years, diagnosed with severe asthma by a physician according to GINA guidelines. They must be using a biologic medication (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab or tezepelumab) and medium or high dose ICS + LABA with or without LAMA and/or SABA via pMDI in combination with a spacer. Additionally, participants must be willing to provide informed consent.

Exclusion Criteria:

Participants are excluded from participation when they are unable to sufficiently understand and read the Dutch language, being pregnant or being terminally ill.

Sample Size:

The study aims to include a total of 110 patients.

Setting:

The study is conducted in five severe asthma clinics across various regions of the Netherlands (Medical Center Leeuwarden, Martini Hospital Groningen, Isala Zwolle, Sint Franciscus Gasthuis, and University Medical Centrer Groningen).

Baseline Assessment:

Participants undergo characterization during an intake visit to the severe asthma clinic, including demographic data, medical history, spirometry tests, FeNO measurement, blood eosinophil count, ACQ assessment, adherence evaluation using TAI, and inhaler technique assessment via checklist. Subsequently, participants receive two fully charged smart spacers, one for each period of three months, along with instructions for use.

Follow-up:

After 4 weeks, participants are contacted to check the functionality of the smart spacer and receive assistance if needed. A follow-up call at 3-months and 9-months into the study remind participants to switch to the next smart spacer. A physical visit is scheduled at the 6-month mark for further assessment, including ACQ administration and collection of smart spacers for replacement.

End of Study Assessment:

At the end of the 12-month study period, participants undergo a final physical visit for assessment of various parameters including FeNO, blood eosinophil count, lung function, ACQ score, inhaler technique, and documentation of exacerbations and OCS use. Smart spacer data analysis is conducted centrally, and feedback is provided to study sites. Additionally, usability and satisfaction surveys are completed by patients and study nurses.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Severe asthma
  • Biologics
  • Digital home monitoring
  • Digital spacer
  • Adherence
  • Inhalation technique
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants aged over 18 years, diagnosed with severe asthma by a physician according to GINA guidelines. They must be using a biologic medication (omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab) and medium or high dose ICS + LABA with or without LAMA and/or SABA via pMDI and spacer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Confirmed asthma diagnoses (≥12% and >200 ml reversibility in or positive histamine/methacholine provocation test or FeNO ≥50) according to the asthma guidelines
  • Diagnosed with severe, asthma with eligibility for treatment with specific asthma biologics (omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab)
  • Using medium or high ICS + LABA +/- LAMA+/-SABA) by pMDI+spacer
  • Willing to sign

Exclusion criteria

Exclusion Criteria:

  • The use of the Symbicort Aerosol or the Trixeo Aerosphere in combination with a spacer (these inhalers are not compatible with the smart spacer)
  • Inability to sufficiently understand and read the Dutch language
  • Current pregnancy
  • Currently terminally ill
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No

Groups and cohorts

  • Severe asthma patients on biologics

    Participants diagnosed with severe asthma using a biologic medication and medium or high dose ICS + LABA with or without LAMA and/or SABA via pMDI and spacer. Participants are being treated at one of the five severe asthma clinics in The Netherlands.

    Device: Smart spacer

Interventions

  • DeviceSmart spacer

    Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).

06

What researchers measure

Primary outcomes

  1. Comparative analysis of smart spacer medication adherence and inhaler technique against Test of Adherence to Inhalers (TAI-12)

    An evaluation of the inhalation adherence patterns and inhaler techniques of patients utilizing smart spacer devices in comparison to traditional inhaler usage assessed by the Test of Adherence to Inhalers (TAI-12). TAI is a questionnaire which identifies patients with low adherence, determines the degree of adherence and gives an idea of the type or pattern of non-compliance. The TAI-12 consists of 10 questions for the patient and 2 questions for the healthcare provider and identifies patients with poor adherence and their degree of adherence. The scoring for the patient part is: for each question ranges from 1 to 5 (1 = worst compliance to 5 = best compliance). All items provide a total score of between 10 (minimum) and 50 (maximum). A higher score is related to better adherence. The scoring of the healthcare provider part is: a minimum of 2 points and a maximum of 4 points. A higher score also relates to a better adherence.

    Time frame: TAI is measured at baseline and 12 months

  2. Comparison of smart spacer medication adherence patterns (adherence and inhaler technique) with inhaler checklist examined by pulmonologist or pulmonary nurse

    An evaluation of the inhalation adherence patterns and inhaler techniques of patients utilizing smart spacer devices in comparison to traditional inhaler usage assessment by healthcare professionals using an inhalation technique checklist. The inhalation technique checklist is created by following the national inhalation technique guidelines by the Lung Foundation in The Netherlands (Long Alliantie Nederland, LAN), specifically for using a pMDI in combination with a spacer. The checklist consists of 8 points to assess the inhalation technique on (from the preparation of the device, to the positioning of the device and posture of the patient, and the actual inhalation).

    Time frame: Inhaler checklist is assessed at baseline and 12 months

Secondary outcomes

  1. Assessing the association of smart spacer assessed adherence with annual exacerbation rate

    An assessment of the association between inhalation medication adherence measured by smart spacer devices and the annual exacerbation rate. The annual exacerbation rate will include the number of exacerbations of the participant in the one-year follow-up and the severity of the exacerbation (e.g. increased reliever use, oral corticosteroid use, emergency room visit, hospitalization).

    Time frame: Over a period of 12 months

  2. Assessing the association of smart spacer assessed adherence with reliever inhaler use (e.g. SABA)

    An examination of the possible association between inhalation medication adherence measured by smart spacer devices and the use of reliever medication. The use of reliever medication will also be monitored by the smart spacer and it is included as a question in the Asthma Control Questionnaire (question 6).

    Time frame: Over a period of 12 months

  3. Assess the association of smart spacer assessed adherence with oral corticosteroids use

    An examination of the possible association between inhalation medication adherence measured through smart spacer devices and the use of oral corticosteroids (OCS). The use of OCS will be defined as total annual OCS exposure (in milligrams) as well as the number of high dose (\> 30 milligrams) short courses (between 3 to 14 days).

    Time frame: Over a period of 12 months

  4. Assess the association of smart spacer assessed adherence with FeNO results

    An examination of the possible association between inhalation medication adherence measured through smart spacer devices and FeNO measurements. Fractional exhaled nitric oxide (FeNO) serves as an indicator of inflammation in asthma. It has been employed as a measure to detect non-compliance with inhaled corticosteroid (ICS) therapy. Individuals who do not adhere to ICS treatment typically exhibit elevated FeNO levels since ICS effectively suppress FeNO. A high FeNO level despite ICS usage suggests ongoing inflammation in the airways due to asthma, increasing the likelihood of exacerbations. The difference in FeNO measured at baseline and 12 months will be compared the overall ICS adherence.

    Time frame: FeNO is measured at baseline and 12 months

  5. Assess the association of smart spacer assessed adherence with blood eosinophils

    An examination of the possible association between inhalation medication adherence measured through smart spacer devices and blood eosinophils. Blood eosinophils are a type of white blood cell that plays a significant role in the immune response, particularly in allergic reactions and inflammatory conditions. Asthma is characterized by chronic inflammation of the airways, and eosinophils are one of the key inflammatory cells involved. Elevated levels of eosinophils in the blood can indicate ongoing inflammation in the airways. Blood eosinophil levels can also serve as a biomarker for predicting response to certain asthma treatments, particularly corticosteroids. Elevated blood eosinophil levels have been associated with an increased risk of asthma exacerbations. The difference in eosinophils measured at baseline and 12 months will be compared the overall ICS adherence.

    Time frame: Blood eosinophils measured at baseline and 12 months

  6. Assess the association of smart spacer assessed adherence with asthma control (ACQ-6)

    An examination of the possible association between adherence measured through smart spacer Asthma Control assessed with the Asthma Control Questionnaire (ACQ-6). This questionnaire consists of six questions about the severity of symptoms which a patient experiences. The score range per question is 0 to 7 (0 = never and 7 = always). The total score will be calculated by dividing the sum of all scores by the amount of questions. A higher score is associated with worse asthma control. The difference in ACQ outcomes at baseline, 6-months and 12 months will be compared the overall ICS adherence.

    Time frame: ACQ is measured at baseline, 6 months and 12 months

  7. Assess the association of smart spacer assessed adherence with spirometry results

    An examination of the possible association between adherence measured through smart spacer devices and spirometry results. Spirometry is a pulmonary function test that measures how much air a person can inhale and exhale, as well as how quickly they can exhale. Asthma often shows a reduced forced expiratory volume in one second (FEV1) and a reduced FEV1 to forced vital capacity (FVC) ratio, indicating obstruction. Lower spirometry readings, particularly a lower FEV1, may indicate poorly controlled asthma, which is associated with an increased risk of exacerbations. Measured: Forced Vital Capacity (FVC) (% pred), Forced Expiratory Volume in one second (FEV1) (% pred), Peak Expiratory Flow (PEF) (L/min), and FEV1/FVC ratio. The difference in spirometry results at baseline and 12 months will be compared the overall ICS adherence.

    Time frame: Spirometry is performed at baseline and 12 months

Other outcomes

  1. Assess usability and patient satisfaction using the System Usability Scale

    The usability and patient satisfaction will be measured using the System Usability Scale (SUS). The SUS provides a simple and standardized effective tool for assessing usability and patient satisfaction with healthcare technologies. The SUS consists of ten statements related to usability, with respondents asked to rate their level of agreement with each statement on a five-point Likert scale ranging from "Strongly Disagree" (1 point) to "Strongly Agree" (5 points). The score for the five odd-numbered questions is determined by subtracting 1 from the scored points (X-1). The score for the five even-numbered questions is calculated by deducting the scored points from 5 (5-X). By adding up these two scores and multiplying the total by 2.5, the SUS score is calculated. The total scores range from 0 to 100. Higher scores indicate better usability, with scores above 70 considered above average and scores above 80 indicating excellent usability.

    Time frame: SUS is measured at 12 months

  2. Assess usability and healthcare provider satisfaction using the System Usability Scale

    The usability and healthcare provider satisfaction will be measured using the System Usability Scale (SUS). The SUS provides a simple and standardized effective tool for assessing usability and healthcare providers' satisfaction with healthcare technologies. The SUS consists of ten statements related to usability, with respondents asked to rate their level of agreement with each statement on a five-point Likert scale ranging from "Strongly Disagree" (1 point) to "Strongly Agree" (5 points). The score for the five odd-numbered questions is determined by subtracting 1 from the scored points (X-1). The score for the five even-numbered questions is calculated by deducting the scored points from 5 (5-X). By adding up these two scores and multiplying the total by 2.5, the SUS score is calculated. The total scores range from 0 to 100. Higher scores indicate better usability, with scores above 70 considered above average and scores above 80 indicating excellent usability.

    Time frame: SUS is measured at 12 months

07

Study locations

5 of 5 sites recruiting
  • Isala
    Zwolle, Overijssel 8025AB, Netherlands
    Recruiting
  • Medisch Centrum Leeuwarden
    Leeuwarden, Provincie Friesland 8934AD, Netherlands
    Recruiting
  • University Medical Center Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
    Recruiting
    • Maarten van den Berge, MD, PhD · Contactm.van.den.berge@umcg.nl · +31 6 24450194
    • Titia Klemmeier, RN · Sub investigator
    • Huib Kerstjens, MD, PhD · Sub investigator
  • Foundation Martini Hospital
    Groningen, Provincie Groningen 9728NT, Netherlands
    Recruiting
    • Marjolein J van Es, MD, PhD · Contactm.vanes@mzh.nl · +31 50 524 5245
  • Stichting Sint Franciscus Vlietland Groep
    Rotterdam, South Holland 3118JH, Netherlands
    Recruiting
08

References and documents

Publications

  • Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042. Epub 2014 Oct 16. PubMed 25441637 ↗
  • McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. Pharmacoeconomics. 2018 Aug;36(8):957-971. doi: 10.1007/s40273-018-0658-x. PubMed 29736895 ↗
  • Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017 Jun 26;18(1):129. doi: 10.1186/s12931-017-0614-x. PubMed 28651591 ↗
  • Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B, Sulaiman I, Brennan V, Lombard L, Walsh J, Plunkett S, McCartan TA, Kerr PJ, Reilly RB, Hughes C, Kent BD, Jackson DJ, Butler M, Counihan I, Hayes J, Faul J, Kelly M, Convery R, Nanzer AM, Fitzgerald JM, Murphy DM, Heaney LG, Costello RW; INCA Research Team. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023 Jul;11(7):591-601. doi: 10.1016/S2213-2600(22)00534-3. Epub 2023 Mar 21. PubMed 36963417 ↗
  • d'Ancona G, Kavanagh J, Roxas C, Green L, Fernandes M, Thomson L, Dhariwal J, Nanzer AM, Jackson DJ, Kent BD. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. Eur Respir J. 2020 May 7;55(5):1902259. doi: 10.1183/13993003.02259-2019. Print 2020 May. PubMed 32060061 ↗
  • d'Ancona G, Kavanagh JE, Dhariwal J, Hearn AP, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Jackson DJ, Kent BD. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma. Allergy. 2021 Jul;76(7):2238-2241. doi: 10.1111/all.14737. Epub 2021 Jan 26. No abstract available. PubMed 33432682 ↗
  • Dekhuijzen R, Lavorini F, Usmani OS, van Boven JFM. Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):785-793. doi: 10.1016/j.jaip.2017.11.027. Epub 2018 Jan 12. PubMed 29339126 ↗
  • van Boven JF, Ryan D, Eakin MN, Canonica GW, Barot A, Foster JM; Respiratory Effectiveness Group. Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):835-46. doi: 10.1016/j.jaip.2016.03.007. PubMed 27587317 ↗
  • O'Dwyer S, Greene G, MacHale E, Cushen B, Sulaiman I, Boland F, Bosnic-Anticevich S, Mokoka MC, Reilly RB, Taylor T, Ryder SA, Costello RW. Personalized Biofeedback on Inhaler Adherence and Technique by Community Pharmacists: A Cluster Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2020 Feb;8(2):635-644. doi: 10.1016/j.jaip.2019.09.008. Epub 2019 Sep 27. PubMed 31568927 ↗
  • Jansen EM, van de Hei SJ, Dierick BJH, Kerstjens HAM, Kocks JWH, van Boven JFM. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. J Thorac Dis. 2021 Jun;13(6):3846-3864. doi: 10.21037/jtd-20-2360. PubMed 34277075 ↗
  • Vincken W, Levy ML, Scullion J, Usmani OS, Dekhuijzen PNR, Corrigan CJ. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018 Jun 18;4(2):00065-2018. doi: 10.1183/23120541.00065-2018. eCollection 2018 Apr. PubMed 29928649 ↗
  • Price DB, Roman-Rodriguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Stallberg B, van der Molen T, Chrystyn H. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1071-1081.e9. doi: 10.1016/j.jaip.2017.01.004. Epub 2017 Mar 9. PubMed 28286157 ↗
  • Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD012286. doi: 10.1002/14651858.CD012286.pub2. PubMed 28288272 ↗
  • Dierick BHJ, Achterbosch M, Been-Buck S, Klemmeier T, van de Hei SJ, Hagedoorn P, Kerstjens HAM, Kocks JWH, van Boven JFM. Can electronic monitoring with a digital smart spacer support personalised medication adherence and inhaler technique education in patients with asthma?: Protocol of the randomised controlled OUTERSPACE trial. BMJ Open. 2022 Jun 13;12(6):e059929. doi: 10.1136/bmjopen-2021-059929. PubMed 35697450 ↗
  • Dierick BJH, Been-Buck S, Klemmeier T, Hagedoorn P, van de Hei SJ, Kerstjens HAM, Kocks JWH, Zijp TR, Wessels AMA, Touw DJ, van Boven JFM. Digital spacer data driven COPD inhaler adherence education: The OUTERSPACE proof-of-concept study. Respir Med. 2022 Sep;201:106940. doi: 10.1016/j.rmed.2022.106940. Epub 2022 Jul 31. PubMed 35933835 ↗
  • Eikholt AA, Wiertz MBR, Hew M, Chan AHY, van Boven JFM. Electronic monitoring devices to support inhalation technique in patients with asthma: A Narrative Review. Curr Treat Options Allergy. 2023; 10:28-52 doi: 10.1007/s40521-023-00328-7.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 31 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Mar 2026 → Dec 2026 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 11, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 2026was Mar 2026
CompletionEst.
Dec 2026was Jun 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 Netherlands)
  • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
  • University Medical Center Groningen · Groningen, Netherlands
  • Foundation Martini Hospital · Groningen, Netherlands
  • Stichting Sint Franciscus Vlietland Groep · Rotterdam, Netherlands
Show 4 removed
  • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
  • Stichting Sint Franciscus Vlietland Groep · Rotterdam, Netherlands
  • University Medical Center Groningen · Groningen, Netherlands
  • Foundation Martini Hospital · Groningen, Netherlands
Nov 16, 2026
Primary completion
Mar 2026→Dec 2026
Nov 16, 2026
Study completion
Jun 2026→Dec 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Netherlands)
    • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
    • University Medical Center Groningen · Groningen, Netherlands
    • Foundation Martini Hospital · Groningen, Netherlands
    • Stichting Sint Franciscus Vlietland Groep · Rotterdam, Netherlands
    Show 4 removed
    • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
    • Stichting Sint Franciscus Vlietland Groep · Rotterdam, Netherlands
    • University Medical Center Groningen · Groningen, Netherlands
    • Foundation Martini Hospital · Groningen, Netherlands
    Primary completion Mar 2026→Dec 2026
    Study completion Jun 2026→Dec 2026
    + 4 other changes: identifiers, verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06360393
Collaborators
Trudell Medical International
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
May 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Job FM van Boven, PharmD, PhD
Contact
j.f.m.van.boven@umcg.nl
+31 50 361 7893
Amber A Eikholt, MSc
Contact
a.a.eikholt@umcg.nl
+31 50 361 7860
Job FM van Boven, PharmD, PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion